Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis.

ABSTRACT:

Background

The nonsteroidal mineralocorticoid antagonist finerenone is a new addition to the list of agents (angiotensin converting enzyme inhibitors and sodium glucose cotransporter 2 inhibitors) conferring renal protection to patients with diabetic kidney disease. Two recent meta-analyses using the fixed effect model in patients with chronic kidney disease (both diabetic and nondiabetic populations) came to a conflicting conclusion on the effect of finerenone on eGFR decline. This meta-analysis was undertaken exclusively in the type 2 diabetes (T2D) population to explore the robustness and heterogeneity of the effect size by conducting a random effects model meta-analysis along with draft plots and prediction intervals.

Materials and methods

A database search was conducted

SUBMITTER: Ghosal S 

PROVIDER: S-EPMC9895809 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature